Clinical trials: Thyroid Cancer Stage I
Cancer
Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer
This is a 2-arm randomized controlled study comparing how effective two therapeutic digital software devices are at improving anxiety and other indicators of psychological and physical health in patients with cancer.
- Trial name
- RESTORE (NCT05227898)
- Testing
- Device: Attune™, Device: Cerena™
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Blue Note Therapeutics
Cancer, Solid Tumor
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Rationale: CALAA-01 is a targeted therapeutic designed to inhibit tumor growth and/or reduce tumor size. The active ingredient in CALAA-01 is a small interfering RNA (siRNA).
- Trial name
- NCT00689065
- Testing
- CALAA-01
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Calando Pharmaceuticals
Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment.
- Conditions
- Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Follicular Carcinoma, Stage I Thyroid Gland Papillary Carcinoma
- Trial name
- NCT01811212
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid…
- Trial name
- NCT04420754
- Testing
- AIC100 CAR T Cells
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- AffyImmune Therapeutics, Inc.
Papillary Thyroid Cancer
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
Thyroid cancers that have spread beyond the neck are not curable. About 30,000 people worldwide die from thyroid cancer every year.
- Trial name
- NCT03469011
- Testing
- Imatinib Oral Tablet
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- AHS Cancer Control Alberta
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
This phase I trial is studying the side effects and best dose of iodine I 131 when given together with pazopanib hydrochloride in treating patients with recurrent and/or metastatic thyroid cancer previously treated with iodine I…
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer
- Trial name
- NCT01413113
- Testing
- pazopanib hydrochloride, iodine I 131
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.
- Trial name
- NCT01661179
- Testing
- Vandetanib 300mg
- Where
- 4 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced Solid Tumor
A Study of KL590586 in Patients With Advanced Solid Tumors
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant…
- Trial name
- NCT05265091
- Testing
- KL590586 Capsule
- Where
- China
- Volunteers
- 414 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma
- Trial name
- NCT01155258
- Testing
- temsirolimus, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Thyroid Neoplasms
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate.
- Trial name
- NCT00094055
- Testing
- AG013736
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Locally Advanced Larynx, Hypopharyngeal Squamous Cell Cancers, Locally Advanced Thyroid Cancers
A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx
This study is a phase I/II dose escalation trial designed to test the feasibility of delivering IMRT to thyroid, larynx and hypopharynx cancer patients, and to assess the safety and possible improvement in outcome when the dose…
- Trial name
- NCT02055989
- Testing
- Dose-escalated radiotherapy level 1, Sequential dose-escalated radiotherapy level 2
- Where
- United Kingdom
- Volunteers
- 105 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
This phase I trial studies the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer.
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma
- Trial name
- NCT01204476
- Testing
- Cixutumumab, Everolimus, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors.
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT04593277
- Testing
- Internet Mobile Technology, Internet-Based Intervention, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 549 people
- Sponsor
- Fred Hutchinson Cancer Center
Medullary Thyroid Cancer
Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
Study in healthy volunteers to assess effect of omeprazole and ranitidine on the pharmacokinetics of vandetanib
- Trial name
- Vandetanib (NCT01539655)
- Testing
- vandetanib, omeprazole, ranitidine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic